Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€6.78

€6.78

-3.480%
-0.24
-3.480%
€14.12
 
27.02.24 / Tradegate WKN: A3DT8V / Symbol: SYRS / Name: Syros Pharmaceuticals / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Syros Pharmaceuticals Inc. Stock

Syros Pharmaceuticals Inc. took a tumble today and lost -€0.240 (-3.480%).
Our community is currently high on Syros Pharmaceuticals Inc. with 4 Buy predictions and 0 Sell predictions.
With a target price of 14 € there is potential for a 106.49% increase which would mean more than doubling the current price of 6.78 € for Syros Pharmaceuticals Inc..
So far the community has only identified positive things for Syros Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Syros Pharmaceuticals Inc. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Syros Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Syros Pharmaceuticals Inc. -3.480% -1.453% 7.278% 91.525% 2.727% -90.712% -
Carbylan Therapeutics Inc -7.410% 2.479% 0.000% 78.777% 14.815% -56.643% -29.745%
Pharma Mar S.A. 1.230% -0.722% -19.512% -40.519% -21.875% -71.053% 84.070%
Clinuvel Pharmaceuticals 4.450% -13.925% -10.219% -32.267% -14.417% -40.129% -49.958%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-06

Upon initial review of the financials for Syros Pharmaceuticals, a company in the volatile pharmaceutical industry, certain numbers immediately draw attention and warrant closer scrutiny. With a market capitalization at approximately $54.98 million and an EBITDA of -$132.625 million, the financial figures suggest the company is in a growth phase but is facing significant challenges in terms of profitability.

General Impressions:

Syros Pharmaceuticals operates in a sector known for high research and development costs, with the potential for substantial returns upon successful product development and approval. This context is essential in understanding why a company might reflect negative earnings before interest, taxes, depreciation, and amortization (EBITDA). Moreover, the lack of dividend payments is common in the industry, as companies often reinvest earnings back into research and product development rather than sharing profits with shareholders.

Comments

Prediction Buy
Perf. (%) 97.65%
Target price 13.598
Change
Ends at 10.08.24

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for SYRS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 93.71%
Target price 14.117
Change
Ends at 03.03.24

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for SYRS provided by MarketBeat
Show more